Search Results

You are looking at 131 - 140 of 372 items for :

  • "therapeutics" x
  • Refine by Access: All x
Clear All
Full access

Thank You, Santa!

Margaret Tempero

therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO Conquer Cancer Foundation Board. She codirected the AACR/ASCO Methods in Clinical Cancer Research and taught this course and similar

Full access

It Just Keeps Getting Better!

Margaret Tempero

research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO Conquer Cancer Foundation

Full access

Giving Thanks

Margaret Tempero

ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO Conquer Cancer Foundation Board. She codirected the AACR

Full access

News About the Tiny Pharmacists Within Us

Margaret Tempero

, MD, is a Professor of Medicine and Director of the UCSF Pancreas Center and editor-in-chief of JNCCN . Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served

Full access

Understanding Cancer Risk—Genes Matter!

Margaret Tempero

Pancreas Center and editor-in-chief of JNCCN . Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She

Full access

Here I Am Again, Santa!

-in-chief of JNCCN . Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO

Full access

NCCN News

, Inc. is a biotechnology company focused on the development of targeted anticancer therapeutics. The company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The company utilizes

Full access

NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022

Featured Updates to the NCCN Guidelines

Craig Horbinski, Louis Burt Nabors, Jana Portnow, Joachim Baehring, Ankush Bhatia, Orin Bloch, Steven Brem, Nicholas Butowski, Donald M. Cannon, Samuel Chao, Milan G. Chheda, Andrew J. Fabiano, Peter Forsyth, Pierre Gigilio, Jona Hattangadi-Gluth, Matthias Holdhoff, Larry Junck, Thomas Kaley, Ryan Merrell, Maciej M. Mrugala, Seema Nagpal, Lucien A. Nedzi, Kathryn Nevel, Phioanh L. Nghiemphu, Ian Parney, Toral R. Patel, Katherine Peters, Vinay K. Puduvalli, Jason Rockhill, Chad Rusthoven, Nicole Shonka, Lode J. Swinnen, Stephanie Weiss, Patrick Yung Wen, Nicole E. Willmarth, Mary Anne Bergman, and Susan Darlow

Therapeutics Inc. Matthias Holdhoff, MD, PhD, Panel Member, has disclosed serving on a data safety monitoring board for Advarra, Inc. and PAREXEL International Corporation; and receiving an honorarium from Pfizer Inc. Seema Nagpal, MD, Panel Member, has

Full access

NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022

Featured Updates to the NCCN Guidelines

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Weina Chen, Bouthaina Dabaja, Megan E. Daly, Leo I. Gordon, Neil Hansen, Alex F. Herrera, Ephraim P. Hochberg, Patrick B. Johnston, Mark S. Kaminski, Christopher R. Kelsey, Vaishalee P. Kenkre, Nadia Khan, Ryan C. Lynch, Kami Maddocks, Jonathan McConathy, Monika Metzger, David Morgan, Carolyn Mulroney, Sheeja T. Pullarkat, Rachel Rabinovitch, Karen C. Rosenspire, Stuart Seropian, Randa Tao, Pallawi Torka, Jane N. Winter, Joachim Yahalom, Joanna C. Yang, Jennifer L. Burns, Mallory Campbell, and Hema Sundar

Laboratories, Inc., and sanofi-aventis U.S.; and grant/research support from Forty Seven, Inc.; Janssen Pharmaceutica Products, LP, Kura Oncology, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Cytier Therapeutics, Pharmacyclics, Regeneron

Full access

Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence

Gary H. Lyman

hematopoietic growth factors . In: Morstyn G Foote M Lieschke GJ , eds. Cancer Drug Discovery and Development. Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics. Totowa, NJ : Humana Press Inc ; 2004 : 409 – 443 . 32